Clinical trial

Attending Physician of Shenzhen People's Hospital

Name
ShenzhenPH spine wang04
Description
Bone mineral density and function at 1 year after screw fixation with denosumab vs zoledronic acid for osteoporotic vertebral compression fractures: a parallel double-blind randomized controlled clinical trial
Trial arms
Trial start
2021-09-08
Estimated PCD
2023-03-05
Trial end
2023-03-11
Status
Recruiting
Phase
Early phase I
Treatment
Denosumab
Denosumab 60mg/6 months subcutaneously + placebo iv
Arms:
denosumab
Other names:
Denosumab 6 month/subcutaneous
Zoledronic acid
Iv zoledronic acid and placebo /6 months subcutaneously
Arms:
zoledronic acid
Other names:
Zoledronic acid intravenous once a year
Size
122
Primary endpoint
age
up to 12 months
sex
up to 12 months
height
up to 12 months
BMI
up to 12 months
serum osteocalcin
up to 12 months
serum Procollagen type 1 n-terminal propeptide P1NP
up to 12 months
serum C-terminal cross-linked type 1 collagen terminal peptide CTX
up to 12 months
Serum total calcium
up to 12 months
lumber spine bone mineral density
up to 12 months
hip bone mineral density
up to 12 months
MRI for lumber
up to 12 months
pain visual analogue scores (VAS)
up to 12 months
Eligibility criteria
Inclusion Criteria: * Must be age between 40 and 90 years old * X-ray diagnosis of 1-2 vertebral compression fractures * Dual eneragy X ray test for bone mineral density T value less than -1 * fracture history lasted within 6 weeks * Must be MRI showed bone marrow edema of injured segment * Must be lower back pain, local spines tenderness Exclusion Criteria: * Must be able to have no posterior vertebral wall fracture * Must be able to have no patients with intervertebral fissure * Must be able to have no infection * Must be able to have no malignancy * Must be able to have no neurological dysfunction * Must be able to have no calcium level ≤2.13 mmol/L * Must be able to have no previous use of anti-osteoporosis drugs * Must be able to have no inability to perform magnetic resonance imaging * Must be able to have no prior back surgery * Must be able to have no other established contraindications for elective surgery
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 122, 'type': 'ESTIMATED'}}
Updated at
2023-02-21

1 organization

2 products

1 indication

Product
Denosumab